Status:
COMPLETED
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Dyslipidemias
Eligibility:
All Genders
30-80 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to evaluate the effectiveness of atorvastatin in lowering cholesterol and getting these high risk patients to their goals of LDL \<115 mg/dl across starting doses of 10 mg,...
Eligibility Criteria
Inclusion
- Dyslipidemia
- At a high risk for coronary heart disease
Exclusion
- Use of higher than usual maintenance doses of statin drugs at screening
- Uncontrolled diabetes or high blood pressure
- Impaired liver function
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2004
Estimated Enrollment :
232 Patients enrolled
Trial Details
Trial ID
NCT00644670
Start Date
June 1 2003
End Date
March 1 2004
Last Update
February 18 2021
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Antwerp, Belgium, 2018
2
Pfizer Investigational Site
Brasschaat, Belgium, 2930
3
Pfizer Investigational Site
Brussels, Belgium, 1180
4
Pfizer Investigational Site
Edegem, Belgium, 2650